Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
104.39
+5.75 (5.83%)
At close: Nov 7, 2025, 4:00 PM EST
102.31
-2.08 (-1.99%)
After-hours: Nov 7, 2025, 7:10 PM EST
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Cidara Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $127.25, which forecasts a 21.90% increase in the stock price over the next year. The lowest target is $35 and the highest is $200.
Price Target: $127.25 (+21.90%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 5 | 5 | 5 | 4 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 11 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $137 → $145 | Buy | Maintains | $137 → $145 | +38.90% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Maintains $100 → $135 | Strong Buy | Maintains | $100 → $135 | +29.32% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +43.69% | Oct 21, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $190 | Buy | Initiates | $190 | +82.01% | Oct 16, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $200 | Buy | Initiates | $200 | +91.59% | Oct 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.28M
Revenue Next Year
7.50M
EPS This Year
-6.13
from -26.75
EPS Next Year
-7.96
from -6.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 30.5M | |||
| Avg | n/a | 7.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.20 | -4.10 | |||
| Avg | -6.13 | -7.96 | |||
| Low | -7.04 | -13.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.